热门资讯> 正文
Avenue Therapeutics在75投1的反向分拆中下跌9%
2024-04-24 19:58
- Specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, Avenue Therapeutics (NASDAQ:ATXI) will effect a 1-for-75 reverse split of stock.
- Avenue expects its common stock to begin trading on a split-adjusted basis on the Nasdaq as of the commencement of trading on April 26, 2024, under the ticker symbol “ATXI.”
- The reverse stock split is intended to bring the company into compliance with Nasdaq’s $1.00 per share minimum bid price requirement for continued listing.
- The stock price declined 9% on Wednesday during pre-market hours of trading.
More on Avenue Therapeutics
- Avenue Therapeutics granted extension for Nasdaq compliance
- Seeking Alpha’s Quant Rating on Avenue Therapeutics
- Historical earnings data for Avenue Therapeutics
- Financial information for Avenue Therapeutics
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
